Collective data upheld its ability to prompt cell cycle arrest and subsequent apoptosis with a disruption in certain regulating proteins including Bax, Bcl-2, Caspase 3 and cytochrome C. These biological outcomes, along with the favorable physicochemical and pharmacokinetic properties, suggest 4b as a potential lead in the design and development of new therapeutic agents for colon cancer. This evidence concerns the gene BCL2 and malignant colon neoplasm.